Investigation of the Host Kinome Response to Coronavirus Infection Reveals PI3K/mTOR Inhibitors as Betacoronavirus Antivirals

• DOI: 10.1021/acs.jproteome.3c00182
• Publication Date: 2023-08-27T12:00:51Z
• Authors: Ethan J. Fritch; Angie L. Mordant; Thomas S.K. Gilbert; Carrow I. Wells; Xuan Yang; Natalie K. Barker; Emily A. Madden; Kenneth H. Dinnon; Yixuan J. Hou; Longping V. Tse; Izabella N. Castillo; Amy C. Sims; Nathaniel J. Moorman; Premkumar Lakshma...; Timothy M. Willson; Laura E. Herring; Lee M. Graves; Ralph S. Baric
• Keywords: Phosphatidylinositol 3-Kinases; SARS-CoV-2; TOR Serine-Threonine Kinases; Middle East Respiratory Syndrome Coronavirus; Humans; COVID-19; MTOR Inhibitors; Hepatitis C, Chronic; Virus Replication; Antiviral Agents; 3. Good health

Host kinases play essential roles in the host cell cycle, innate immune signaling, the stress response to viral infection, and inflammation. Previous work has demonstrated that coronaviruses specifically target kinase cascades to subvert host cell responses to infection and rely upon host kinase activity to phosphorylate viral proteins to enhance replication. Given the number of kinase inhibitors that are already FDA approved to treat cancers, fibrosis, and other human disease, they represent an attractive class of compounds to repurpose for host-targeted therapies against emerging coronavirus infections. To further understand the host kinome response to betacoronavirus infection, we employed multiplex inhibitory bead mass spectrometry (MIB-MS) following MERS-CoV and SARS-CoV-2 infection of human lung epithelial cell lines. Our MIB-MS analyses revealed activation of mTOR and MAPK signaling following MERS-CoV and SARS-CoV-2 infection, respectively. SARS-CoV-2 host kinome responses were further characterized using paired phosphoproteomics, which identified activation of MAPK, PI3K, and mTOR signaling. Through chemogenomic screening, we found that clinically relevant PI3K/mTOR inhibitors were able to inhibit coronavirus replication at nanomolar concentrations similar to direct-acting antivirals. This study lays the groundwork for identifying broad-acting, host-targeted therapies to reduce betacoronavirus replication that can be rapidly repurposed during future outbreaks and epidemics. The proteomics, phosphoproteomics, and MIB-MS datasets generated in this study are available in the Proteomics Identification Database (PRIDE) repository under project identifiers PXD040897 and PXD040901.